Suchergebnisse - "Burns, Gareth S."

PubPharm (5)

1

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

enthalten in: Hepatology communications | 2023

von Thompson, A. | Jackson, K. | Bonanzinga, S. | +25

2

Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways

enthalten in: The Journal of infectious diseases | 2022

von Hall, S. | Burns, G. | Mooney, B. | +23

3

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B : a meta-analysis

enthalten in: Gut | 2022

von Hall, S. | Vogrin, S. | Wawryk, O. | +4

CommentIn: Gut. 2022 Jun;71(6):1238-1240. - PMID 34670810

4

Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients : HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Hall, S. | Burns, G. | Anagnostou, D. | +21

CommentIn: Aliment Pharmacol Ther. 2022 Aug;56(3):544-545. - PMID 35804472

5

Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients : HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

enthalten in: Alimentary Pharmacology & Therapeutics | 2022

von Hall, S. | Burns, G. | Anagnostou, D. | +21

1
[1]